Insertable variable fragments of antibodies and modified A1-A2 domains of NKG2D ligands
K Landgraf, DP Steiger, SR Williams… - US Patent …, 2022 - Google Patents
US11453713B2 - Insertable variable fragments of antibodies and modified A1-A2 domains
of NKG2D ligands - Google Patents US11453713B2 - Insertable variable fragments of …
of NKG2D ligands - Google Patents US11453713B2 - Insertable variable fragments of …
Insertable variable fragments of antibodies and modified α1-α2 domains of NKG2D ligands
K Landgraf, DP Steiger, SR Williams… - US Patent …, 2021 - Google Patents
This application relates generally to the production of polypeptides having specific antigen-
binding properties of Fv domains, for example, insertable variable fragments of antibodies …
binding properties of Fv domains, for example, insertable variable fragments of antibodies …
Insertable variable fragments of antibodies and modified α1-α2 domains of NKG2D ligands, and non-natural NKG2D ligands that bind non-natural NKG2D receptors
K Landgraf, DP Steiger, T Baron, D Gebhart - US Patent 10,259,858, 2019 - Google Patents
US10259858B2 - Insertable variable fragments of antibodies and modified α1-α2 domains of
NKG2D ligands, and non-natural NKG2D ligands that bind non-natural NKG2D receptors …
NKG2D ligands, and non-natural NKG2D ligands that bind non-natural NKG2D receptors …
Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives
T Spies, V Spies - US Patent App. 10/648,978, 2004 - Google Patents
Therefore, in a first embodiment, there is provided a method for expanding a human T-cell
population that expresses a natural or engineered NKG2D comprising con tacting said …
population that expresses a natural or engineered NKG2D comprising con tacting said …
Antibody heavy chain variable domains targeting the nkg2d receptor
GP Chang, AF Cheung, W Haney… - US Patent App. 16 …, 2020 - Google Patents
Antibody heavy chain variable domains that can be paired with any of a variety of antibody
light chain variable domains to form an antigen binding site targeting the NKG2D receptor …
light chain variable domains to form an antigen binding site targeting the NKG2D receptor …
Antibodies binding to NKG2D
S Dengl, G Georges, R Hosse, I Waldhauer… - US Patent …, 2023 - Google Patents
The present invention generally relates to antibodies that bind to NKG2D, including
multispecific antigen binding molecules eg for activation of T cells and/or NK cells. In …
multispecific antigen binding molecules eg for activation of T cells and/or NK cells. In …
Modified non-natural NKG2D ligands that selectively deliver attached heterologous molecules to non-natural NKG2D receptors on car-cells
This application relates generally to the production of modified, non-natural α1-α2 domains
of NKG2D ligands with attached polypeptides having specific target-binding properties, for …
of NKG2D ligands with attached polypeptides having specific target-binding properties, for …
Anti-nkg2a antibodies and uses thereof
PJL Spee, SB Padkaer - US Patent App. 16/397,271, 2019 - Google Patents
Described herein are anti-NKG2A antibodies suitable for human therapy, including
humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and …
humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and …
Anti-NKG2A antibodies and uses thereof
PJL Spee, SB Padkaer - US Patent 9,683,041, 2017 - Google Patents
Described herein are anti-NKG2A antibodies suitable for human therapy, including
humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and …
humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and …
Anti-NKG2A antibodies and uses thereof
PJL Spee, SB Padkær - US Patent 8,206,709, 2012 - Google Patents
Described herein are anti-NKG2A antibodies suitable for human therapy, including
humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and …
humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and …